Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial.

Rheumatology (Oxford) 2013 Jul 14;52(7):1214-9. Epub 2013 Feb 14.

Janssen Research & Development, LLC, Spring House, PA, USA.

Objective: To evaluate the effects of the anti-TNF-α monoclonal antibody golimumab, administered by s.c. injection or i.v. infusion, on markers of inflammation in patients with RA.

Methods: In this phase 1, open-label study, patients with active RA were randomized to receive s.c. golimumab 100 mg at baseline and every 4 weeks through week 20 (n = 33; group 1) or i.v. golimumab 2 mg/kg at baseline and week 12 (n = 16; group 2). Serum levels of CRP, IL-6, serum amyloid A (SAA), TNF receptor II (TNFRII), MMP-3, hyaluronic acid, haptoglobin, ferritin and haemoglobin and serum/urine hepcidin were measured at various time points. Associations between the biomarkers were assessed with Spearman's correlations.

Results: In both groups 1 and 2, decreases in mean serum levels of CRP, IL-6, SAA, TNFRII, MMP-3, haptoglobin, ferritin and hepcidin, and mean urine levels of hepcidin occurred within 1 week and were sustained through week 8. Decreases in concentrations of serum CRP, IL-6, SAA, MMP-3, hepcidin, ferritin and haptoglobin and urine hepcidin were maintained through week 24 in group 1, but began to reverse after week 8 in group 2. Among all patients, decreases in serum hepcidin correlated significantly with decreases in serum CRP and ferritin.

Conclusion: Decreases in serum and urine concentrations of markers of inflammation occurred as early as 24 h after treatment with golimumab, and most of these improvements were sustained through week 24 in group 1.

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/kes381DOI Listing
July 2013
16 Reads

Publication Analysis

Top Keywords

week group
20
decreases serum
16
crp il-6
12
tnfrii mmp-3
8
sustained week
8
haptoglobin ferritin
8
serum crp
8
markers inflammation
8
il-6 saa
8
levels crp
8
serum levels
8
serum
7
week
7
hepcidin
6
decreases
5
group
5
golimumab
5
associations biomarkers
4
assessed spearman's
4
biomarkers assessed
4

Similar Publications